Contract analysis

I. Executive Summary This memorandum provides a comprehensive quantitative and qualitative comparison of the two resolution paths now available to Optiwave Semiconductor Corp. ("OWS") following Lumos Photonics, Inc.'s ("Lumos") March 22, 2023 walk-away counteroffer. The two paths are as follows: (A) Accept the Walk-Away Settlement: Mutual general releases of all claims and counterclaims, zero payment in either direct

II. Background and Procedural Posture A. Case Overview Plaintiff. Optiwave Semiconductor Corp. ("OWS") is a Delaware corporation headquartered in San Jose, California. OWS is a fabless semiconductor company that designs and develops silicon photonics integrated circuits and optical interconnect solutions for data center and telecommunications applications. For fiscal year 2022, OWS reported total revenue of approxima

III. Option A: Accept the Walk-Away Settlement A. Terms of Lumos's Walk-Away Proposal Lumos's March 22, 2023 walk-away proposal, as communicated by Victoria Ashworth of BHS, consists of the following terms:

1. No Monetary Payment. Zero dollars ($0) to be paid by either party to the other. Each party walks away without making or receiving any payment.

2. Mutual General Releases. Both parties execute mutual general releases of all claims, counterclaims, cross-claims, and causes of action arising from or related to the litigation styled Optiwave Semiconductor Corp. v. Lumos Photonics, Inc., Case No. 5:22-cv-03417-EJD (N.D. Cal.). The releases would cover all claims that were asserted or could have been asserted in connection with the four patents-in-suit and the acc

3. No License. No license is granted by either party to the other under any patent, trade secret, copyright, or other intellectual property right. OWS retains all rights in its patent portfolio. Lumos retains all rights in its patent portfolio.

4. Each Party Bears Its Own Costs. Each party bears its own attorneys' fees, expert fees, costs, and expenses incurred in connection with the litigation. No cost-shifting, fee-shifting, or reimbursement of any kind.

5. No Admissions. Neither party admits infringement, non-infringement, validity, invalidity, enforceability, or unenforceability of any patent. Neither party admits any fault, liability, or wrongdoing of any kind.

6. Dismissal with Prejudice. The parties agree to file a Joint Stipulation of Dismissal with Prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all claims and counterclaims with prejudice, with each party bearing its own costs.

7. Settlement Agreement and Mutual Release. The parties agree to execute a written Settlement Agreement and Mutual Release memorializing the foregoing terms. The agreement would include standard provisions regarding integration, governing law, counterparts, and confidentiality. The proposed terms are straightforward and customary for walk-away settlements. There are no unusual provisions, restrictive covenants, or hi

IV. Option B: Continue Litigation Through Trial A. Remaining Litigation Phases and Estimated Costs If OWS rejects the walk-away and elects to continue litigating, the case will proceed through several remaining phases, each of which will generate substantial additional costs. The following cost estimates are based on C&H's experience in comparable patent cases in the Northern District of California, the specific circ

1. Infringement Viability Post-Markman The Markman Order has fundamentally undermined OWS's infringement theories. We assess each patent individually below: '567 Patent — Infringement Untenable. The Court's construction of "adiabatically coupled" as requiring a "gradual, continuous taper designed and configured to prevent excitation of higher-order modes over the entire transition length" directly and unambiguously e

2. Invalidity Risk Lumos's counterclaims for invalidity under 35 U.S.C. §§ 102 and 103, and for unenforceability under 35 U.S.C. § 112, remain live and pose a meaningful risk to OWS's patent portfolio. The key prior art references and invalidity theories are as follows: (a) '567 Patent — Tanaka (U.S. 9,456,012). Lumos contends that the '567 Patent is anticipated by the Tanaka reference, which discloses an adiabatic c

3. Damages Risk Even If Infringement Proven Even in the unlikely event that OWS were able to prove infringement on one or more claims of the '890 Patent (the only patent with any residual infringement theory), the damages recovery would be dramatically reduced from OWS's original expectations. OWS's damages expert, Dr. Lawrence Kessler of Apex Claim Analytics, prepared a preliminary damages analysis in Q4 2022 that p

V. Comparative Summary Table The following table provides a side-by-side comparison of the two options available to OWS: The table makes clear that on every dimension — cost, expected recovery, risk, management burden, portfolio impact, and timeline — the walk-away is the superior outcome.

VI. Analysis of Alternative Settlement Structures Before recommending acceptance of the walk-away as offered, we have considered whether alternative settlement structures might yield a better outcome for OWS. We have identified three theoretical alternatives and assess each below. A. Cross-License with Nominal Royalty (Previously Proposed and Rejected) On March 15, 2023, OWS proposed a settlement consisting of a cros

VII. Impact on Fee Arrangement and Retainer The following summarizes the financial status of the matter and the impact of the walk-away on C&H's fee arrangement and r